Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.
Identifieur interne : 000097 ( PubMed/Checkpoint ); précédent : 000096; suivant : 000098Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.
Auteurs : Carrie E. Barnes [Australie] ; C Raina Macintyre [Australie]Source :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2019.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antibactériens (pharmacologie), Co-infection (microbiologie), Co-infection (mortalité), Co-infection (traitement médicamenteux), Co-infection (épidémiologie), Femelle, Grippe humaine (), Grippe humaine (épidémiologie), Humains, Jeune adulte, Mâle, Pandémies (), Pneumonie à pneumocoques (microbiologie), Pneumonie à pneumocoques (mortalité), Pneumonie à pneumocoques (épidémiologie), Pneumonie à pneumocoques (étiologie), Résistance bactérienne aux médicaments, Streptococcus pneumoniae (), Streptococcus pneumoniae (génétique), Streptococcus pneumoniae (physiologie), Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antipneumococciques (administration et posologie), Vaccins antipneumococciques (génétique), Vaccins antipneumococciques (immunologie).
- MESH :
- administration et posologie : Vaccins antigrippaux, Vaccins antipneumococciques.
- effets indésirables : Vaccins antigrippaux.
- génétique : Streptococcus pneumoniae, Vaccins antipneumococciques.
- immunologie : Vaccins antipneumococciques.
- microbiologie : Co-infection, Pneumonie à pneumocoques.
- mortalité : Co-infection, Pneumonie à pneumocoques.
- pharmacologie : Antibactériens.
- physiologie : Streptococcus pneumoniae.
- traitement médicamenteux : Co-infection.
- épidémiologie : Co-infection, Grippe humaine, Pneumonie à pneumocoques.
- étiologie : Pneumonie à pneumocoques.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Pandémies, Résistance bactérienne aux médicaments, Streptococcus pneumoniae, Vaccination.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-Bacterial Agents (pharmacology), Coinfection (drug therapy), Coinfection (epidemiology), Coinfection (microbiology), Coinfection (mortality), Drug Resistance, Bacterial, Female, Humans, Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza, Human (complications), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Middle Aged, Pandemics (prevention & control), Pneumococcal Vaccines (administration & dosage), Pneumococcal Vaccines (genetics), Pneumococcal Vaccines (immunology), Pneumonia, Pneumococcal (epidemiology), Pneumonia, Pneumococcal (etiology), Pneumonia, Pneumococcal (microbiology), Pneumonia, Pneumococcal (mortality), Streptococcus pneumoniae (drug effects), Streptococcus pneumoniae (genetics), Streptococcus pneumoniae (physiology), Vaccination, Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines, Pneumococcal Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , genetics : Pneumococcal Vaccines.
- chemical , immunology : Pneumococcal Vaccines.
- chemical , pharmacology : Anti-Bacterial Agents.
- complications : Influenza, Human.
- drug effects : Streptococcus pneumoniae.
- drug therapy : Coinfection.
- epidemiology : Coinfection, Influenza, Human, Pneumonia, Pneumococcal.
- etiology : Pneumonia, Pneumococcal.
- genetics : Streptococcus pneumoniae.
- microbiology : Coinfection, Pneumonia, Pneumococcal.
- mortality : Coinfection, Pneumonia, Pneumococcal.
- physiology : Streptococcus pneumoniae.
- prevention & control : Influenza, Human, Pandemics.
- Adolescent, Adult, Drug Resistance, Bacterial, Female, Humans, Male, Middle Aged, Vaccination, Young Adult.
Abstract
The aim of this study was to estimate the impact of antimicrobial resistance (AMR) in secondary pneumococcal pneumonia infections on global mortality during the 2009 influenza pandemic, to estimate future pandemic mortality risk and to inform pandemic preparedness.
DOI: 10.1016/j.ijid.2019.05.005
PubMed: 31096052
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:31096052Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.</title><author><name sortKey="Barnes, Carrie E" sort="Barnes, Carrie E" uniqKey="Barnes C" first="Carrie E" last="Barnes">Carrie E. Barnes</name><affiliation wicri:level="3"><nlm:affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. Electronic address: carrie.barnes@dhhs.vic.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health and Community Medicine, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C Raina" last="Macintyre">C Raina Macintyre</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31096052</idno><idno type="pmid">31096052</idno><idno type="doi">10.1016/j.ijid.2019.05.005</idno><idno type="wicri:Area/PubMed/Corpus">000136</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000136</idno><idno type="wicri:Area/PubMed/Curation">000136</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000136</idno><idno type="wicri:Area/PubMed/Checkpoint">000097</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000097</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.</title><author><name sortKey="Barnes, Carrie E" sort="Barnes, Carrie E" uniqKey="Barnes C" first="Carrie E" last="Barnes">Carrie E. Barnes</name><affiliation wicri:level="3"><nlm:affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. Electronic address: carrie.barnes@dhhs.vic.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Public Health and Community Medicine, University of New South Wales, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C Raina" last="Macintyre">C Raina Macintyre</name><affiliation wicri:level="3"><nlm:affiliation>The Kirby Institute, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Kirby Institute, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="eISSN">1878-3511</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-Bacterial Agents (pharmacology)</term><term>Coinfection (drug therapy)</term><term>Coinfection (epidemiology)</term><term>Coinfection (microbiology)</term><term>Coinfection (mortality)</term><term>Drug Resistance, Bacterial</term><term>Female</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (complications)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Pandemics (prevention & control)</term><term>Pneumococcal Vaccines (administration & dosage)</term><term>Pneumococcal Vaccines (genetics)</term><term>Pneumococcal Vaccines (immunology)</term><term>Pneumonia, Pneumococcal (epidemiology)</term><term>Pneumonia, Pneumococcal (etiology)</term><term>Pneumonia, Pneumococcal (microbiology)</term><term>Pneumonia, Pneumococcal (mortality)</term><term>Streptococcus pneumoniae (drug effects)</term><term>Streptococcus pneumoniae (genetics)</term><term>Streptococcus pneumoniae (physiology)</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antibactériens (pharmacologie)</term><term>Co-infection (microbiologie)</term><term>Co-infection (mortalité)</term><term>Co-infection (traitement médicamenteux)</term><term>Co-infection (épidémiologie)</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies ()</term><term>Pneumonie à pneumocoques (microbiologie)</term><term>Pneumonie à pneumocoques (mortalité)</term><term>Pneumonie à pneumocoques (épidémiologie)</term><term>Pneumonie à pneumocoques (étiologie)</term><term>Résistance bactérienne aux médicaments</term><term>Streptococcus pneumoniae ()</term><term>Streptococcus pneumoniae (génétique)</term><term>Streptococcus pneumoniae (physiologie)</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antipneumococciques (administration et posologie)</term><term>Vaccins antipneumococciques (génétique)</term><term>Vaccins antipneumococciques (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Streptococcus pneumoniae</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coinfection</term><term>Influenza, Human</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Streptococcus pneumoniae</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Streptococcus pneumoniae</term><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Co-infection</term><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Coinfection</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coinfection</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Co-infection</term><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antibactériens</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Streptococcus pneumoniae</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Streptococcus pneumoniae</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Co-infection</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Co-infection</term><term>Grippe humaine</term><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Drug Resistance, Bacterial</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Vaccination</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Résistance bactérienne aux médicaments</term><term>Streptococcus pneumoniae</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to estimate the impact of antimicrobial resistance (AMR) in secondary pneumococcal pneumonia infections on global mortality during the 2009 influenza pandemic, to estimate future pandemic mortality risk and to inform pandemic preparedness.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31096052</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.</ArticleTitle><Pagination><MedlinePgn>1-6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(19)30211-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2019.05.005</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to estimate the impact of antimicrobial resistance (AMR) in secondary pneumococcal pneumonia infections on global mortality during the 2009 influenza pandemic, to estimate future pandemic mortality risk and to inform pandemic preparedness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Risk analysis modelling was conducted using a multivariate risk formula. Literature reviews were conducted to generate global central estimates for each of the parameters of the risk formula in relation to the 2009 influenza pandemic, secondary pneumococcal pneumonia, rates of AMR, and pneumococcal vaccine efficacy as a component of pandemic preparedness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Global Streptococcus pneumoniae AMR was estimated at 21.8% to 27.6%, and contributed to 1.8% to 2.3% of deaths during the 2009 influenza pandemic. When directly applied to mortality due to multidrug resistance, pneumococcal vaccination could potentially prevent 1277 to 3754 deaths and could have reduced mortality from multidrug-resistant S. pneumoniae to 1% to 1.2%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AMR in secondary pneumococcal infections contributed towards a small percentage of the global mortality during the 2009 influenza pandemic. Increased S. pneumoniae AMR could result in a three- to four-fold rise in mortality due to secondary pneumococcal infections in future influenza pandemics. Pneumococcal vaccination has an important role in preventing pneumococcal co-infections and combating AMR in all populations, and should be considered a key component of influenza pandemic preparedness or early action plans.</AbstractText><CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Carrie E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia. Electronic address: carrie.barnes@dhhs.vic.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacIntyre</LastName><ForeName>C Raina</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>The Kirby Institute, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024881" MajorTopicYN="Y">Drug Resistance, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011018" MajorTopicYN="N">Pneumonia, Pneumococcal</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">Pandemic influenza</Keyword><Keyword MajorTopicYN="N">Secondary pneumococcal pneumonia</Keyword><Keyword MajorTopicYN="N">Streptococcus pneumoniae</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31096052</ArticleId><ArticleId IdType="pii">S1201-9712(19)30211-5</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2019.05.005</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Nouvelle-Galles du Sud</li></region><settlement><li>Sydney</li></settlement></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Barnes, Carrie E" sort="Barnes, Carrie E" uniqKey="Barnes C" first="Carrie E" last="Barnes">Carrie E. Barnes</name></region><name sortKey="Macintyre, C Raina" sort="Macintyre, C Raina" uniqKey="Macintyre C" first="C Raina" last="Macintyre">C Raina Macintyre</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000097 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000097 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:31096052
|texte= Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:31096052" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |